SS-31
SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome[3]. This educational protocol presents a once‑daily subcutaneous approach using concentrated reconstitution for practical insulin‑syringe measurements.
Reconstitution Steps
Draw 1.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
Gently swirl/roll until fully dissolved (clear solution).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.
Protocol Overview
Concise summary of the once‑weekly regimen.
Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand.
Schedule: Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).
Dose Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).
Reconstitution: 1.0 mL per 10 mg vial (10 mg/mL) for convenient single‑syringe administration.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 5 mg daily for Weeks 1–2 to assess individual tolerance.
Standard Target: 10 mg daily by Week 3 (most common clinical trial dose).
Advanced Target: 15–20 mg daily for Weeks 5+ (only for severe conditions under medical oversight).
Frequency: Once per day (subcutaneous injection); maintain consistent timing.
Cycle Length: 8–12 weeks; limited data exists beyond 12 weeks.
Timing: Any consistent time; rotate injection sites to prevent tissue irritation.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for months when frozen.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 4 weeks for optimal stability.
Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if needed to minimize temperature fluctuations.
Allow refrigerated vials to reach room temperature before opening to reduce condensation inside the vial.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.
Mild injection‑site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials, these typically resolve within hours.
Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns.
For doses requiring split injections (≥15 mg), space injections at least 2 inches apart on different body regions.
How This Works
SS‑31 (elamipretide) is a cell‑permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction[1]. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure[2][7]. By stabilizing cardiolipin‑protein interactions, SS‑31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues[8].
Preclinical research demonstrated that SS‑31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia‑reperfusion injury, neurodegeneration, chronic kidney disease, and age‑related muscle atrophy[9]. In human clinical trials, SS‑31 showed favorable safety and tolerability profiles with no dose‑limiting toxicities[4][5]. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six‑minute walk distance, leading to FDA accelerated approval in 2025[3][10].
Potential Benefits
Stabilizes mitochondrial membranes and optimizes electron transport chain function[1][2].
Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues[8].
Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity)[3][10].
Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy[9].
Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials[4].
Common Side Effects:
Injection‑site reactions (most common): Mild‑to‑moderate redness, itching, or transient discomfort at injection site; typically resolves within hours[4][6].
Approximately 80% of patients in clinical trials experienced mild injection‑site reactions[6].
No dose‑limiting toxicities or serious adverse events directly attributed to SS‑31 in published trials[4][5].
Long‑term safety data beyond 12 weeks remains limited; extended use requires monitoring.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Nutrition: Emphasize mitochondrial cofactors including B‑vitamins, CoQ10, magnesium, and alpha‑lipoic acid; maintain adequate protein intake to support muscle maintenance.
Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.
Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.
Stress Management: Chronic stress increases oxidative burden; incorporate stress‑reduction practices such as meditation, breathwork, or yoga.
Avoid Mitotoxins: Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.
